Ambioinfusions Aid Infants With Fetal Kidney Failure Lung Hypoplasia

Serial amnioinfusions administered during pregnancy successfully mitigated lethal lung hypoplasia in over a third of infants born following pregnancies complicated by anhydramnios due to fetal kidney failure. The findings stem from the nonrandomized RAFT study, which tracked outcomes for these high-risk pregnancies. Lung hypoplasia, a condition where the lungs do not develop fully, is a primary cause of mortality in neonates with severe oligohydramnios or anhydramnios resulting from chronic fetal kidney dysfunction.

The RAFT study involved 29 pregnancies diagnosed with fetal kidney failure and anhydramnios. Amnioinfusions were performed serially, with fluid being instilled into the amniotic sac. This intervention aimed to restore amniotic fluid volume, which is crucial for normal fetal lung development. The study reported that 11 out of the 29 infants (37.9%) survived to discharge from the hospital, indicating a significant positive impact of the amnioinfusion therapy.

Prior to the widespread adoption of amnioinfusions for this specific condition, the prognosis for infants born with anhydramnios due to fetal kidney failure was exceedingly poor, with survival rates often cited as very low due to the severity of lung hypoplasia. The RAFT study's results suggest that amnioinfusions can offer a viable therapeutic option, providing a critical window for lung maturation and improving survival outcomes for these vulnerable neonates. Further research may explore optimal timing and frequency of infusions.